Inappropriate Sinus Tachycardia: Etiology, Pathophysiology, and Management: JACC Review Topic of the Week.
cardiac dysautonomia
inappropriate sinus tachycardia
sinus node modification
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
21 06 2022
21 06 2022
Historique:
received:
03
02
2022
revised:
31
03
2022
accepted:
01
04
2022
entrez:
16
6
2022
pubmed:
17
6
2022
medline:
22
6
2022
Statut:
ppublish
Résumé
Inappropriate sinus tachycardia (IST) is a clinical syndrome that generally affects young patients and is associated with distressing symptoms. Although the most common symptom is palpitations, it can be accompanied by a myriad of symptoms, including anxiety, dizziness, presyncope, and syncope. The pathogenesis of IST is not well understood and considered multifactorial, with autonomic dysfunction being the central abnormality. IST is a diagnosis of exclusion. Management presents a clinical challenge. The overall efficacy of lifestyle modifications and medical therapy may be limited. Recent advances in catheter and surgical sinus node sparing ablation techniques have led to improvement in outcomes. In addition, increased focus has led to development of multimodality team-based interventions to improve outcomes in this group of patients. In this review, we discuss the mechanistic basis of IST, review current approaches to diagnosis, and outline contemporary therapeutic approaches.
Identifiants
pubmed: 35710196
pii: S0735-1097(22)04825-2
doi: 10.1016/j.jacc.2022.04.019
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2450-2462Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures Dr Lakkireddy has been a consultant for Johnson & Johnson, Abbott, Biotronik, Pfizer, and Boston Scientific. Dr Gopinathannair has been a consultant/speaker for Abbott Medical, Boston Scientific, and Biosense Webster. Dr Olshansky has been a consultant for Sanofi; Chair of DSMB REDUCE IT–Amarin; and U.S. coordinator of GLORIA AF at Boehringer Ingelheim. Dr Russo has provided research support at Boston Scientific, Kestra, Medilynx, and Medtronic; has been a consultant for Abbott, Atricure, Biosense Webster, Boston Scientific, Medtronic, and PaceMate; has received honoraria from Biotronik, Bristol Myers Squibb/Pfizer, and Medtronic; and has received royalties from Up-to-Date. Dr LaMeier has been a consultant at Atricure. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.